Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence.
Eli Lilly and Insilico Medicine have struck a new deal on AI-driven drug discovery, the companies announced on Sunday.
ADVERTISEMENT
ADVERTISEMENT
Under the agreement, worth up to $2.75 billion (€2.39 billion), the American firm Eli Lilly will use Insilico’s artificial intelligence (AI) platform to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.
“From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery,” said Alex Zhavoronkov, founder and CEO of Insilico Medicine.
“Working with Lilly, we aim to deliver transformative therapies that treat diseases with high unmet need. This collaboration is a testament to the power of AI in tackling the most complex challenges in human health,” he added.
Insilico Medicine is a global, clinical-stage, generative AI-driven biotechnology company. It integrates biology, chemistry, and clinical analysis through its Pharma.AI platform to identify novel disease targets and design new drug molecules.
Under the deal, Eli Lilly will have exclusive worldwide license for the development, manufacturing, and commercialisation of novel oral therapeutics in preclinical development for certain indications, the companies said.
“Insilico’s AI-enabled discovery capabilities represent a powerful complement to Lilly’s deep expertise in clinical development across multiple therapeutic areas,” said Andrew Adams, group vice president of molecule discovery at Eli Lilly.
He added that the partnership would allow the company to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas.
Under the terms of the agreement, Insilico will receive a $115 million (€100 million) upfront payment, which could be increased by development, regulatory, and commercial milestones that could bring the total deal value to approximately $2.75 billion (€2.39 billion), plus tiered royalties on future sales.
